GlassScriptPhysician profile
Sarah A Digiorgi
NPI 1588776348
$4,961.87
in general payments reported to CMS, 2019-2025
36 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $393 · 2021: $419 · 2022: $332 · 2023: $1,650 · 2024: $711 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266 · Education: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.24 |
| Education | $1,269.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,390.68 | 2023-2025 | Davinci Xi |
| Astellas Pharma US INC | $518.43 | 2021-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $380.74 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $238.50 | 2019-2025 | Aptima |
| Lsi Solutions INC | $223.60 | 2024 | Ram |
| Merck Sharp & Dohme LLC | $218.12 | 2021-2025 | Gardasil 9, Gardasil |
| Abbvie INC. | $201.74 | 2019-2022 | |
| Pfizer INC. | $200.31 | 2019-2024 | |
| Medtronic, INC. | $181.97 | 2025 | Corevalve Evolut R |
| Mayne Pharma Commercial LLC | $181.39 | 2021-2025 | |
| Amgen INC. | $167.95 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $142.25 | 2023 | Exparel |
| Exact Sciences Corporation | $108.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $106.40 | 2021-2025 | |
| Dysis Medical, INC. | $100.03 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $82.06 | 2021-2023 | Nexplanon |
| Myovant Sciences INC. | $60.64 | 2021-2022 | |
| Coopersurgical, INC. | $51.70 | 2019-2024 | Wallach Cryosurgical Equipment |
| Therapeuticsmd, INC. | $50.40 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $49.25 | 2023-2025 | Myfembree |
| Myriad Women'S Health, INC. | $46.51 | 2023 | Myrisk |
| Channel Medsystems, INC. | $35.21 | 2023-2025 | |
| Covidien LP | $31.32 | 2019 | |
| Millicent US INC | $29.41 | 2020 | |
| Urovant Sciences INC | $26.57 | 2022 | |
| Radius Health, INC. | $16.64 | 2019 | |
| Avanos Medical | $16.38 | 2019 | |
| Evofem Biosciences, INC. | $14.23 | 2021 | |
| Agile Therapeutics, INC. | $14.17 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.84 | 2021 | |
| Allergan, INC. | $13.80 | 2019 | |
| Daiichi Sankyo INC. | $13.57 | 2020 | |
| Lupin INC. | $13.27 | 2019 | |
| Avion Pharmaceuticals | $11.41 | 2020 | |
| Medicem INC. | $11.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Digiorgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.